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Abstract
Background: Hepatitis G virus (HGV) is an RNA virus. It is mainly transmitted through exposure to
contaminated blood although other routes may also exist. Patients with chronic renal failure (CRF) are at
high risk of acquiring HGV because they require frequent blood transfusions. Ongoing HGV infection can
be only diagnosed by demonstrating viremia in patient sample by reverse transcriptase (RT) PCR.
Antibodies to the envelop protein E2 (anti E2) of HGV is an indicator of virus clearance and testify past
HGV contact. This cross sectional study was done to assess the frequency of HGV exposure (ongoing and
past infection) in Egyptian children with CRF and to study the possible risk factors of infection.
Methods: This study included 100 children with CRF [34 on regular haemodialysis (HD) and 66 before
the start of dialysis (predialysis)]. All patients sera were tested for HGV RNA by RT-PCR, anti E2, hepatitis
C virus (HCV) antibody, hepatitis B surface antigen (HBsAg), and hepatitis B core antibody (HBcAB).
Twenty five healthy children of matched age & sex were used as controls.
Results: HGV RNA was positive in 9 (26.5%) of HD and 9 (13.6%) of predialysis children. Anti E2 was
positive in 14 (41.2%) of HD and 19 (28.8%) of predialysis children.
In comparison to controls; CRF (n = 100); HD and predialysis children had significantly higher prevalence
of anti E2 [4% VS 33% for all CRF cases; (p = 0.002)& 41.2% (p = 0.002) and 28.8% (p = 0.01); for HD and
predialysis groups; respectively]. HGV RNA was significantly more prevalent only in HD children in
comparison to controls (p = 0.03). HD and predialysis children did not have significant difference in the
prevalence of HGV RNA (p = 0.16) or anti E2 (p = 0.26).
HGV exposure was not correlated with positivity of anti HCV (p = 0.32), HCV RNA (0.09), HBsAg/HBcAB
(p = 1), age (p = 0.06), or gender (p = 0.83). It was significantly correlated with duration of the disease (p
< 0.001). Ongoing HGV infection was significantly more prevalent with frequent blood transfusion (p <
0.001). There were no significant differences in serum levels of ALT (p = 0.09), total bilirubin (p = 0.1) and
albumin (p = 0.06) in children with ongoing infection in comparison to healthy controls.
Conclusions: The frequency of HGV exposure in Egyptian children with CRF appears to be high and is
mainly related to frequent blood transfusions and longer disease duration. HGV infection in these children
is not associated with significant changes in hepatic biochemical parameters.
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Background
Infections are one of the important causes of morbidity
and mortality in patients with end stage renal failure[1].
Chronic hepatitis is a major complication of chronic
haemodialysis (HD). Initially; hepatitis B virus (HBV)
infection was the most common etiologic agent of chronic
hepatitis in patients on chronic HD. Later; after HBV vac-
cines became available and measures for screening and
exclusion of hepatitis B surface antigen (HBsAg) positive
blood were routinely used, HBV infection dropped signif-
icantly. Subsequently; however, hepatitis C virus (HCV)
emerged as a new problem. In USA; rates of positive anti
HCV reached up to 36% in HD patients in 1990s [2].
Two different laboratories in the USA isolated a new flavi-
virus-like RNA virus in the years 1995 and 1996. The first
laboratory named it "G B virus-C (GBV-C)" and the other
"hepatitis G virus (HGV)". Both viruses were subsequently
considered different genotypes of the same virus because
they were found to share most of the nucleotide and
amino acid sequences [3]. Both viruses have a single
stranded RNA genome of approximately 9.4 kb. It
encodes a single poly protein of 2900 amino acids in
which the non structural proteins are located at the C ter-
minal end and the structural proteins at the N terminal
end [4]. The HGV genome encodes an open reading frame
coding for two envelop proteins (E1 & E2) [5].
The ongoing HGV infection can be diagnosed by demon-
stration of viremia in patient blood by reverse tran-
scriptase (RT)-PCR. An assay detecting antibodies to the
envelop protein E2 (anti E2) of HGV has been developed
and this serological marker is considered to be an indica-
tor of the virus clearance [6,7]. Thus; the presence of anti
E2 seems to indicate past HGV exposure and is associated
with immunity and protection from reinfection [8].
Blood transfusion is the main risk factor for HGV trans-
mission [9]. Patients with chronic renal failure (CRF) usu-
ally require frequent blood transfusions which make them
more vulnerable to HGV infection [10,11]. The present
data on the prevalence of HGV anti E2 in HD patients is
conflicting, with studies showing rates of 7% in Japan [12]
up to 29% in Germany [13]. Up to our knowledge there
are no published data on the prevalence of HGV infection
in Egyptian children with CRF.
HGV associated hepatitis runs with normal biochemical
parameters in 75% of patients [14]. Although HGV infec-
tion appears to be not associated with severe hepatic dam-
age; however a possible link between HGV infection and
acute [15-17], fulminant hepatitis [18-21], chronic (mild
and moderate) hepatitis [22,23] or even hepatic fibrosis
[24] has been suggested. This study was done to assess the
frequency of HGV exposure (ongoing & past infection) in
Egyptian children with CRF and to correlate viral exposure
with age, sex, duration of disease, frequency of blood
transfusion, and co infection with HBV & HCV and to
study the effect of ongoing viral infection on hepatic bio-
chemical parameters in these children.
Methods
This cross sectional study was carried out at Mansoura
University Children's Hospital Nephrology Unit, Egypt in
the period from January till June 2008. The study involved
100 children (67 males & 33 females) with CRF. Their
ages ranged from 2 to 18 years [median (Interquartile
range; IQR) = 9 (5-14) years]. Written concents were
obtained from the parents of children and the study was
approved by the ethical committee of the university.
Among the studied patients; 34 children (19 males & 15
females) were on regular HD for a mean duration of 5.1 ±
2.1 years and the remaining 66 children (48 males & 18
females) were on medical therapy without a need to
receive dialysis with mean disease duration of 2.4 ± 0.94
years.
A questionnaire was used to collect sociodemographic
data such as age, sex, number of previous blood transfu-
sions and duration of the disease. A group of 25 randomly
chosen apparently healthy children of matched age and
sex served as a control group.
Five mls. of blood samples were withdrawn from patients
and controls. They were centrifuged and serum was sepa-
rated. Serum was stored in aliquots at -70°C. Repeated
freezing and thawing was avoided. All the biochemical
parameters were done by routine laboratory methods
unless otherwise mentioned. HBsAg, Total hepatitis B core
antibody (HBcAB) and Anti HCV antibody were detected
with commercially available enzyme linked immunosorb-
ent assay (Equipar, 21047 Saronno VA, Italy). Serum
alanine aminotransferase (ALT) values were measured by
Hitachi 902 auto analyzer (Roche, Switzerland). HGV
Anti E2 was detected by ELISA and HGV RNA by RT - PCR.
HBsAg
This kit uses double antibody (sandwich) ELISA method,
in which polystyrene microwell strips are pre-coated with
antibody to HBsAg. Patients samples are added to the
microwells together with a second antibody; horseradish
peroxidase (HRP-Conjugate). During incubation the spe-
cific immunocomplex formed in case of presence of
HBsAg in the sample, is captured on the solid phase. After
washing, chromogen solution containing Tetramethyl-
benzidine (TMB) is added to the wells in presence of the
antibody -antigen -antibody (HRP) immunocomplex, the
colorless chromogens are hydrolyzed by the bound HRP
conjugate to a blue colored product. The blue color turnsAnnals of Clinical Microbiology and Antimicrobials 2009, 8:36 http://www.ann-clinmicrob.com/content/8/1/36
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yellow after the reaction is stopped with sulfuric acid. The
intensity of color is proportional to the amount of antigen
captured in the wells, and to the sample respectively.
HbcAb
HBcAb test uses the principle of competitive immu-
noassay technique for the detection of antibodies to HBc
in human serum. During the assay, the test specimen and
HRP-HBcAb conjugates are incubated simultaneously
with the coated microwells. HBcAb if present in the spec-
imen will compete with HRP-HBcAb for the constant
amount of Hbc antigen coated on the microwells surface.
Thus the amount of HRP-HBcAb bound to the well is
inversely proportion to the concentration of HBcAb in the
specimen. Unbounded conjugated are then removed by
washing. The presence of the HRP-complex is shown by a
blue color upon additional incubation with TMB sub-
strate.
HCV-Ab
This kit employs solid phase ELISA method for detection
of antibodies to HCV in two step incubation procedure.
Polystyrene microwell strips are precoated with recom-
binant antigens corresponding to the core and the non-
structural regions of HCV. During the first incubation
step, specific HCV-Ab, if present, are captured on the solid
phase. The wells are washed and anti-human igG antibod-
ies conjugated to the enzyme (HRP - Conjugate) are
added. During the second incubation step, these HRP
Conjugate antibodies bind to any antigen antibody com-
plexes previously formed and the unbound HRP Conju-
gate is then removed by washing. Chromogen solution
containing TMB is added to the wells in presence of the
antigen-antibody-anti-IgG (HRP) immunoconplex which
is hydrolyzed to a blue colored product. The blue color
turns yellow after the reaction is stopped with sulfuric
acid. The intensity of color can be measured and it is pro-
portional to the amount of antibody captured in the wells,
and to the amount of antibody in the sample respectively.
Hitachi 902
A random access fully automated chemistry analyzer with
a throughput up 200 tests per hour and up to 300 tests
with optional ion selective electrode. The Roche/Hitachi
902 test menu comprises clinical chemistry, protein pro-
filing and therapeutic drug monitoring. It is able to con-
solidate routine testing and support specials testing assays
and a choice of over 100 different assay applications.
HGV Anti E2 Testing
All of the samples were tested with a commercial Enzyme-
linked Immunosorbent Assay (Anti-H Genv EIA; Boe-
hringer, GmbH, Mannheim, Germany) for the detection
of specific IgG antibodies against HGV E2 protein. Anti-
bodies to the E2-protein of HGV were detected by a two-
step sandwich enzyme immunoassay [7]. Serum samples
or controls were diluted in sample buffer and were added
to coated microtiter wells. The microplate was incubated
and washed then a solution containing peroxidase-conju-
gated anti-human IgG antibody was added. After incuba-
tion at room temperature and the addition of chromogen
substrate, the optical density was measured at 405 nm
within 10 minutes. All the incubation steps were per-
formed using a shaker. Results were interpreted according
to the manufacturer's instruction.
RT-PCR for HGV RNA
Total RNA was extracted from 100 μL of serum using an
RNA easy Mini kit (Qiagen, Valencia, California, USA).
The isolated RNA was used for reverse transcription (RT)
and first round PCR. RT-PCR was performed in a single
tube using RT-PCR System (Promega, Madison, WI). Both
first and second-round PCR were carried out using prim-
ers that hybridize to 5' non-translated regions of an infec-
tious GBV-C clone (GenBank accession no. AF121950, nt
54 to 389). Primers for the first-round RT-PCR were
GBVF1 5'-CCGACGCCTATCTAAGTA GACGC and GBVR1
5'-TCAACTCGCCGGATAAA-CCTATTGG. Primers for the
second-round PCR were GBVF2 5'-GTGACAGGGTT-
GTAGG and GBVR2 5'-GACATTGAA-GGG-CGACGTGG.
PCR products were detected on 1.5% agarose gels contain-
ing 0.5 μg/ml ethidium bromide. The expected band sizes
were 336 and 231 bp for the first- and second-round PCR;
respectively. A reaction was considered positive if either
the first- or second-round PCR produced a band of the
expected size [25].
Qualitative HCV RNA detection (Cobas Amplicor, Roche 
Diagnostics)
The amplicor HCV RNA detection is based on five major
processes; specimen preparation, reverse transcriptase of
target RNA to generate complementary DNA, PCR ampli-
fication of target DNA using HCV complementary prim-
ers, hybridization of the amplified products to
oligonucleotide probes specific to the targets and detec-
tion of the probe - bound amplified products by colori-
metric determination. The master mix reagent has been
developed to insure equivalent detection of all known
genotypes of HCV at concentration of 50 Iu/ml.
Statistical analysis
Data was analyzed by SPSS (Statistical Package for Social
Sciences) under Windows (version 10). Numerical data
were found to have a non parametric distribution by Kol-
mogorov Smirnov test. Data were expressed as median
and interquartile range (IQR) or when indicated as abso-
lute numbers and percentages. Tests used included Chi
square and Mann Whitney test. P value less than 0.05 was
considered significant.Annals of Clinical Microbiology and Antimicrobials 2009, 8:36 http://www.ann-clinmicrob.com/content/8/1/36
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Results
Table 1 gives the frequency of HGV, HCV and HBV mark-
ers in the two groups of patients and controls. Among the
100 CRF patients; HGV exposure (ongoing and past infec-
tion) was found in (51\100) 51% of children. HGV RNA
and Anti E2 were not detected simultaneously in any
patient. Among the HD group: HGV RNA, anti E2 anti-
bodies, HBsAg; HbcAB, HCV RNA and anti HCV were pos-
itive in (9/34) 26.5%; (14/34) 41.2%; (2/34) 5.9%; (2/
34) 5.9%; (33/34) 97% and (32/34) 94.1% of patients;
respectively.
In the predialysis group: (9/66) 13.6%; (19/66) 28.8%;
(3/66) 4.5%; (3/66) 4.5%; (25/66) 37.9% and (20/66)
30.3% of patients tested positive for HGV RNA, Anti E2,
HBsAg, HbcAB. HCV RNA and anti HCV; respectively.
HGV RNA was detected in significantly more children on
HD (26.5%) than in controls (4%) (p = 0.03). On the
other hand; in comparison to controls; all CRF, HD and
predialysis children had significantly higher prevalence of
anti E2 [4% vs. 33% for all CRF cases; (p = 0.002), 41.2%
(p = 0.002) and 28.8% for HD and predialysis groups (p
= 0.01); respectively].
HD and predialysis children did not have significant dif-
ference in the prevalence of HGV RNA (p = 0.16) or anti
E2 (p = 0.26).
Demographic and virological markers were compared
between children with HGV exposure (ongoing infection
or past infection) and those who were not exposed. HGV
exposure was not related to age (p = 0.06), sex (p = 0.83),
history of blood transfusion (p = 0.15), co infection with
HCV (p = 0.09) or HBV (p = 1). HGV exposed patients had
significantly longer disease duration in comparison to
none exposed patients (p < 0.001), (Table 2).
The number of blood transfusions was studied in relation
to ongoing HGV infection. Patients with ongoing infec-
tion had significantly more frequent blood transfusion in
the last 12 months preceding sampling in comparison to
patients without ongoing infection [median (Interquartile
range; IQR) = 9 (7-24) Vs 2 (0-5) times; p < 0.001; respec-
tively].
The significance of HGV viraemia in the liver biochemis-
try was also studied. There were no significant differences
in serum levels of ALT (p = 0.09), total bilirubin (p = 0.1)
and albumin (p = 0.06) in children with ongoing infec-
tion in comparison to healthy controls, (Table 3).
Discussion
In the current work, the frequency of HGV exposure was
(28/66) 42.4% in predialysis children with CRF and
increased to (23/34) 67.6% in HD children. It was 51%
(51/100) in the total group of CRF children and only 8%
in healthy controls.
Patients with chronic renal failure have a great risk to
acquire HGV infection because they usually need frequent
blood transfusions [26]. HGV RNA prevalence in chronic
dialysis adult patients has been studied in different coun-
tries with somehow conflicting results. HGV RNA preva-
lence rates in HD patients ranged from 11.5 to 27% in the
USA [27,28], from 6-57.5% in Europe [11,16] and in Asia,
from less than 2.2% in India [29] to 55% in Indonesia
[30]. In contrast, few reports are available on HGV preva-
lence in children. HGV RNA is prevalent in 6.3% of
healthy American children [31], only in 0.5% of healthy
Japanese children [32], in 21% of Pakistani children with
Beta thalassaemia [33], in 13% of Italian children with
thalassaemia [34] and in 18.5% of American children
with CRF [35]. As Egypt is one of the countries world wide
suffering from high prevalence of hepatotropic viruses
[36]; it is not surprising to find a high frequency of HGV
exposure in the studied children.
Although a positive correlation between the prevalence of
HGV infection and the history and/or amounts of blood
transfusion have been reported in some studies [37,38];
other studies have found no such connections [16,39]. In
our study; HGV exposure was not significantly different in
children with and without history of blood transfusion;
however patients with ongoing infection have signifi-
cantly more frequent blood transfusions in the last 12
months preceding sampling in comparison to patients
without ongoing infection. These apparently opposing
findings can be explained easily if we took into consider-
ation that a large number of our patients had history of
blood transfusion. 49/51 (96%) of HGV exposed patients
Table 1: Frequency of HGV RNA, Anti E2, HBsAg, HbcAB, HCV RNA and Anti HCV in patients and controls.

















Total (100) 51 (51%) 18 (18%) 33 (33%) 5 (5%) 5 (5%) 58 (58%) 52 (52%)
Controls (25) 2 (8%) 1 (4%) 1 (4%) 0 0 0 0Annals of Clinical Microbiology and Antimicrobials 2009, 8:36 http://www.ann-clinmicrob.com/content/8/1/36
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and 43/49 (87.7%) of HGV non exposed patients had his-
tory of blood transfusion. Our centre is a tertiary referral
facility and most of our patients present to us during late
stages of renal diseases after they have received blood
transfusion for treatment of anemia of CRF in their pri-
mary health care facilities. Thus when we studied HGV
exposure in relation to history of blood transfusion; we
did not find significant difference between patients with
and without history of blood transfusion. It is logic to
think that every blood transfusion session carries a poten-
tial risk of getting blood borne infection and that the
number of blood transfusions should be considered in
evaluating the potential risk of getting any blood borne
infection; so when we studied the relation between ongo-
ing HGV infection and the number of blood transfusions
in the last 12 months before sampling; we found that
HGV infection was significantly more common with fre-
quent transfusions.
Several other non parenteral routes of infection have been
suggested for HGV infection such as percutaneous con-
tamination from saliva [40], maternal-fetal vertical trans-
mission [41] and nosocomial infection through patient to
patient transmission [42]. In our study, HGV exposed
patients had significantly longer disease duration in com-
parison to none exposed patients. We believe that longer
disease duration could increase the chance to get HGV
infection through exposure to increasing numbers of
blood transfusion and/or more exposure to the above
mentioned suggested non parenteral modes of infection.
Numerous authors have studied the association between
HCV and HGV infection with variable results [39,43,44].
HGV co infection has been reported in up to 21% [45] of
patients with chronic HCV infection. Fabrizi et al.,
reported that the frequency of anti HCV antibody was sig-
nificantly higher in HGV positive than in HGV negative
patients on chronic HD treatment and that the rate of co
infection was 82% [46]. On the other hand, none of HGV
positive HD patients were found to be co infected with
HCV in an Italian [47] and Iranian study [48]. In our study
the prevalence of HGV in the HCV RNA positive group
was not significantly different than in the HCV RNA neg-
ative group. Therefore HGV and HCV appear to be trans-
mitted independently as previously reported [47,48].
Some studies have reported coinfection between HGV and
HBV in dialysis patients with rates varying from 2.3 to
13% in HD patients [39,49,50]. Other studies have not
found any association between these viral infections [51].
In our study; only 5% of CRF children were positive for
HBsAg and HBcAB. Again there was no significant differ-
ence in the prevalence of HGV infection between HBsAg/
HBcAB positive and negative children.
The simultaneous detection of HGV RNA and anti E2 is
uncommon and appears just before clearance, probably
in the form of immunocomplex [52]. In the current work;
none of the anti E2 positive patients tested positive for
HGV RNA. Similarly none of the HGV RNA positive
patients was serologically positive. This confirms that the
appearance of the antibody is accompanied by clearance
of HGV RNA. Similar findings have been previously
reported [7,53].
In the current study, serum ALT, total bilirubin and albu-
min levels were not significantly elevated in children with
Table 2: Comparison of different parameters in patients with and without HGV exposure.
HGV Exposed HGV None Exposed P
Number of patients 51 49 -
Age (years) 7 (5-13) 9 (7-15) 0.06*
Sex (M : F) 35 : 16 32 : 17 0.83**
HBsAg (+) 32 1 . o * *
HCV RNA (+) 26 (50.1%) 32 (65.3%) 0.09**
History of blood
transfusion (+)
49 (96%) 43 (87.7%) 0.15**
Duration (years) 3 (3-5) 2 (2-3) < 0.001*
Values expressed as percentages or median and IQR
* Mann Whitney test
**Chi Square test
Table 3: Comparison of liver biochemistry in children with 
positive HGV RNA and controls.
Patients Controls p*
Albumin (Gm/dl) 4 (3.8-4) 4 (3.9-4.2) 0.06
Total bilirubin (mg/dl) 0.9 (0.8-1) 0.8 (0.8-0.9) 0.1
ALT (U/L) 27 (21.7-33) 23 (20.5-28) 0.09
Values expressed as median and IQR
* Mann Whitney testAnnals of Clinical Microbiology and Antimicrobials 2009, 8:36 http://www.ann-clinmicrob.com/content/8/1/36
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ongoing infection in comparison to controls. Although
children with ongoing infection had slightly elevated
serum ALT levels in comparison to controls [median
(IQR) 27 (21.7-33) Vs 23 (20.5-28) U/L; respectively);
this was not statistically significant. HGV infection was
reported to be associated with acute [15-17] up to fulmi-
nant hepatitis [18-21]. On the contrary; other researchers
have suggested that in most instances HGV infection does
not cause an elevation of ALT levels [37]. Histopathologic
examination of liver biopsies revealed no differences
between patients with HCV infection alone and patients
who were co infected with HGV [54]. Pessoa et al;
reported that the hepatic to serum median ratio of HGV
RNA was less than 1, in contrast to HCV which is present
in high ratio [55]. The current work suggests that HGV
infection in children with CRF does not cause significant
elevation in ALT levels and therefore there is no strong
indication to consider HGV as an etiologic agent of symp-
tomatic hepatitis in these children. Another possible
explanation is the small number of children with ongoing
infection in our study (18 patients) which may have
affected the relevance of ALT values in comparison to con-
trols. A study of larger number of children with ongoing
HGV infection is required.
Conclusion
In summary, the frequency of HGV exposure in Egyptian
children with CRF appears to be high and is mainly
related to frequent blood transfusions and longer disease
duration. HGV infection in these children is not associ-
ated with significant changes in hepatic biochemical
parameters.
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